Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
HeartWare secondary offering grosses $62.8 million: Ventricular assist device developer grosses $62.8 million from a secondary offering of 1.77 million shares of common stock at $35.50 per share, completed Feb. 2. HeartWare International plans to use the proceeds for "general corporate and working capital purposes," the company states. The firm's HeartWare miniature ventricular assist system with HVAD pump is being assessed in a 150-patient U.S. trial for use as a bridge to transplant, and the company expects to begin a pivotal study in mid-2010 for use as an alternative to transplant (1"The Gray Sheet" Dec. 7, 2009). The underwriters for the stock offering included JP Morgan Securities, Canaccord Adams, Lazard Capital Markets and Wedbush PacGrow Life Sciences
You may also be interested in...
Piper Jaffray Healthcare Conference In Brief
Boston Scientific strategic review: Firm expects to complete a strategic review of its business, including "redoing the pipeline," by year-end, CEO Ray Elliott said during a Dec. 1 presentation at the Piper Jaffray Healthcare Conference in New York. Elliott, who took over the chief executive role from Jim Tobin in July, has cited improving marketing operations as a main priority; however, he also has signaled an interest in product diversification to include more women's health and urology projects (1"The Gray Sheet" July 27, 2009). While the company aspires to grow sales in the mid-single digits, "that's going to require some product mix changes and some emphasis changes, because it's very tough to get mid or even higher single-digit numbers with two-thirds of the business obviously positioned" in drug-eluting stents and cardiac rhythm management markets, which have lately experienced slower growth, he said. Boston Scientific recently reported third quarter sales of $2.025 billion, up 2% (2"The Gray Sheet" Oct. 26, 2009)
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.